BioSpace News Archive

Biotech Beach

Inari Medical to Participate in the 2024 Bank of America Securities Healthcare Conference

Inari Medical, Inc. announced its management team will present at the upcoming Bank of America Securities Healthcare Conference on Wednesday, May 15, 2024, at 11:20 AM Pacific Time.

May 6, 2024
·
1 min read
Drug Development

EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy

EyePoint Pharmaceuticals, Inc. announced topline results of its Phase 2 PAVIA clinical trial evaluating DURAVYU™, previously known as EYP-1901, in patients with non-proliferative diabetic retinopathy.

May 6, 2024
·
11 min read
Drug Development

IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the Swedish Medical Products Agency has approved the initiation of a Phase I clinical study of the drug candidate IRL757.

May 6, 2024
·
4 min read
Pharm Country

Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca

Cellectis announced that, following clearance from the French Ministry of Economy and satisfaction of all other closing conditions, AstraZeneca completed the additional equity investment of $140M in Cellectis, as previously announced by Cellectis on November 1 and 15, 2023.

May 6, 2024
·
3 min read
Lone Star Bio

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism

Lantern Pharma Inc. announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications.

May 6, 2024
·
15 min read
Policy

MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

MannKind Corporation announced that the U.S. Food and Drug Administration has granted Fast Track designation of Clofazimine Inhalation Suspension for the treatment of nontuberculous mycobacterial lung disease.

May 6, 2024
·
4 min read
Genetown

Oculis to Present at Bank of America Global Healthcare Conference

Oculis Holding AG a global biopharmaceutical company purposefully driven to save sight and improve eye care, announced that Oculis’ management will be attending and presenting at the Bank of America Healthcare Conference taking place on May 14-16, 2024 in Las Vegas, NV.

May 6, 2024
·
1 min read
Pharm Country

Immunic to Participate in Investor and Scientific Conferences in May 2024

Immunic, Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced participation in the following investor and scientific conferences in May.

May 6, 2024
·
6 min read
Pharm Country

A Novel Broad-Spectrum Antiviral with Activity Against Influenza A

NanoViricides, Inc., a global leader in broad-spectrum antiviral nanomedicines, says that the ultra-broad antiviral activity spectrum of NV-387 includes Influenza A viruses, possibly including Bird Flu H5N1 virus as well.

May 6, 2024
·
8 min read
Genetown

Neumora Therapeutics to Participate in Upcoming Conferences in May 2024

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, announced that the Company will participate in two investor conferences in May.

May 6, 2024
·
1 min read